695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

已完结 10 由 wuhu 发布于 2025/10/21 21:48:22

DOI:10.1136/jitc-2023-sitc2023.0695
作者：Parneet Cheema, Sylvia Hartl, Marianna Koczywas, Maximilian Hochmair, Frances A Shepherd, Quincy Chu, Giuseppe Galletti, Mark Gustavson, Sonia Iyer, J Carl Barrett, Brent Evans, Rakesh Kumar, Jan Cosa
文献类型：期刊论文
补充材料：只需要正文

BMJ

Abstract：Background The HUDSON platform study (NCT03334617) explores investigational therapies in patients (pts) with NSCLC who progressed on immune checkpoint inhibitors (ICIs) to overcome immune re

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierUrban water resources accounting based on industrial interaction perspective: Data preparation, accounting framework, and case study